OR WAIT null SECS
November 10, 2016
The agreement allows Bristol-Myers Squibb exclusive license to manufacture and commercialize Nitto Denko Corporation’s NASH treatment.
November 08, 2016
British artificial intelligence company BenevolentAI has signed an exclusive license for a series of novel clinical-stage drug candidates with Johnson & Johnson.
November 07, 2016
The study in 48 healthy adults will assess the safety and immunogenicity of a prime-boost regime of two different intranasal doses of the RSV vaccine, SynGem.
November 04, 2016
Researchers in the University of Dundee have discovered a new method of activating drugs to combat visceral leishmaniasis. The discovery could lead to better treatments for neglected tropical diseases.
German biotech ARTES and Iranian biopharma manufacturer BioSun will develop an HPV vaccine.
The company invested more than €250 in production in China.
November 03, 2016
CFDA granted Pfizer China approval for the company’s Prevenar 13 vaccine.
November 02, 2016
Astellas will acquire Ganymed and its portfolio of ideal monoclonal antibody candidates.
Bellicum and Ospedale Pediatrico Bambino Gesù will collaborate on preclinical and clinical development of CAR-T and TCR therapeutics.
November 01, 2016
Oxford Genetics has secured a GBP1 million capital from investment group Mercia Technologies to support its growth strategy in delivering new services for cancer-fighting gene-therapy technologies.